# Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

> **NCT04223648** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy

## Key facts

- **NCT ID:** NCT04223648
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08-15
- **Primary completion:** 2022-02
- **Final completion:** 2025-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2021-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04223648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04223648, "Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04223648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*